Current drug discovery methods often fail to address the complexity of diseases at the protein level, leading to ineffective treatments and a lack of precise therapeutic targets. Traditional approaches struggle to simulate disease on a molecular level, hindering the identification of novel drug candidates.

Protai offers a vertically integrated platform for drug discovery that leverages mass spectrometry-derived proteomics data and machine learning to simulate disease biology. The AIMS™ platform facilitates the identification of novel therapeutic targets and improves the development of effective treatments by precisely targeting complex disease drivers. By unlocking proteins in their native states, Protai transforms disease treatment through a deep understanding of protein networks, post-translational modifications, and complex structures. The platform integrates structural and functional proteomics data with AI to highlight innovative drug mechanisms and discover best-in-class drug candidates.

AIMS™ platform integrates structural and functional mass spectrometry proteomics data and AI

Identification of novel therapeutic targets

Advanced protein simulations to discover novel best-in-class medicines

Target redefinition, drug discovery and optimization, and deep MOA understanding

Disease- and modality-agnostic pipeline

Focus on validated drug targets in oncology and immunology

The primary customers are pharmaceutical companies and academic labs seeking to collaborate on drug discovery and development, target redefinition, and mechanism of action understanding.